» Articles » PMID: 36448938

Scaling Genetic Resources: New Paradigms for Diagnosis and Treatment of Rare Genetic Disease

Overview
Specialty Genetics
Date 2022 Nov 30
PMID 36448938
Authors
Affiliations
Soon will be listed here.
Abstract

Development of genetic tests for rare genetic diseases has traditionally focused on individual diseases. Similarly, development of new therapies occurred one disease at a time. With >10,000 rare genetic diseases, this approach is not feasible. Diagnosis of genetic disorders has already transcended old paradigms as whole exome and genome sequencing have allowed expedient interrogation of all relevant genes in a single test. The growth of newborn screening has allowed identification of diseases in presymptomatic babies. Similarly, the ability to develop therapies is rapidly expanding due to technologies that leverage platform technology that address multiple diseases. However, movement from the basic science laboratory to clinical trials is still hampered by a regulatory system rooted in traditional trial design, requiring a fresh assessment of safe ways to obtain approval for new drugs. Ultimately, the number of nucleic acid-based therapies will challenge the ability of clinics focused on rare diseases to deliver them safely with appropriate evaluation and long-term follow-up. This manuscript summarizes discussions arising from a recent National Institutes of Health conference on nucleic acid therapy, with a focus on scaling technologies for diagnosis of rare disorders and provision of therapies across the age and disease spectrum.

Citing Articles

mRNA therapy as primary and bridge therapy for inborn errors of metabolism.

Vockley J Mol Ther. 2025; 33(3):842-843.

PMID: 39986270 PMC: 11897746. DOI: 10.1016/j.ymthe.2025.02.010.


The Revolution of Genetic Diagnosis: An Example from Rare Disorders.

Zampatti S Genes (Basel). 2024; 15(10).

PMID: 39457452 PMC: 11507123. DOI: 10.3390/genes15101328.


Newborn sequencing is only part of the solution for better child health.

Brunelli L, Sohn H, Brower A Lancet Reg Health Am. 2023; 25:100581.

PMID: 37663526 PMC: 10474049. DOI: 10.1016/j.lana.2023.100581.


Moving away from one disease at a time: Screening, trial design, and regulatory implications of novel platform technologies.

Lekstrom-Himes J, Brooks P, Koeberl D, Brower A, Goldenberg A, Green R Am J Med Genet C Semin Med Genet. 2023; 193(1):30-43.

PMID: 36738469 PMC: 10038900. DOI: 10.1002/ajmg.c.32031.

References
1.
Goldenberg A, Marie Comeau A, Grosse S, Tanksley S, Prosser L, Ojodu J . Evaluating Harms in the Assessment of Net Benefit: A Framework for Newborn Screening Condition Review. Matern Child Health J. 2016; 20(3):693-700. PMC: 4819963. DOI: 10.1007/s10995-015-1869-9. View

2.
Luther D, Lee Y, Nagaraj H, Scaletti F, Rotello V . Delivery approaches for CRISPR/Cas9 therapeutics in vivo: advances and challenges. Expert Opin Drug Deliv. 2018; 15(9):905-913. PMC: 6295289. DOI: 10.1080/17425247.2018.1517746. View

3.
Longo N, Sass J, Jurecka A, Vockley J . Biomarkers for drug development in propionic and methylmalonic acidemias. J Inherit Metab Dis. 2022; 45(2):132-143. PMC: 9303879. DOI: 10.1002/jimd.12478. View

4.
De Vivo D, Bertini E, Swoboda K, Hwu W, Crawford T, Finkel R . Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study. Neuromuscul Disord. 2019; 29(11):842-856. PMC: 7127286. DOI: 10.1016/j.nmd.2019.09.007. View

5.
. Ten great public health achievements--worldwide, 2001-2010. MMWR Morb Mortal Wkly Rep. 2011; 60(24):814-8. View